HAIFA, Israel, Oct. 13, 2016 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading developer of placenta-based
cell therapy products, today announced its Chairman and CEO, Zami Aberman, has been re-elected as Member of the Board of Directors
of the Alliance for Regenerative Medicine (ARM). This is Mr. Aberman’s second year serving on the Board of the Washington,
D.C.-based, international organization that represents the gene therapy, cell therapy and tissue engineering sector. Pluristem has
been a member of ARM for 4 years and has actively supported the organization’s goals.
Mr. Aberman will work with fellow board members, officers and executive committee members of ARM who come from the leading
companies and institutions in regenerative medicine, to set the overall vision and direction of ARM.
“I am honored to be re-elected to the Board of ARM. Over the past year, Pluristem has made a meaningful
contribution to this very important organization, which advances the regenerative medicine industry for the benefit of patients and
healthcare systems around the globe,” stated Pluristem CEO Zami Aberman.
About The Alliance for Regenerative Medicine
The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative,
regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide.
ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business
development and investor outreach services to support the growth of its member companies and research organizations. Prior to the
formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests
of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community.
Today, ARM has more than 225 members and is the leading global advocacy organization in this field. To learn more about ARM or to
become a member, visit http://www.alliancerm.org.
About Pluristem Therapeutics
Pluristem Therapeutics Inc. is a leading developer of placenta-based cell therapy products. The Company has
reported robust clinical trial data in multiple indications for its patented PLX (PLacental eXpanded) cells. The cell products
release a range of therapeutic proteins in response to inflammation, ischemia, hematological disorders, and radiation damage. PLX
cell products are grown using the Company's proprietary three-dimensional expansion technology. They are off-the-shelf, requiring
no tissue matching prior to administration.
Pluristem has a strong intellectual property position; Company-owned and operated, GMP-certified manufacturing
and research facilities; strategic relationships with major research institutions; and a seasoned management team.
Contact: Pluristem Therapeutics Inc. Karine Kleinhaus, MD, MPH Divisional VP, North America 1-914-512-4109 karinek@pluristem.com
